Innoviva, Inc. business relationships
Companies named in Innoviva, Inc.’s 10-K filed 2026-02-25, and public companies whose annual reports name Innoviva, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 70 / 100 Top 1% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Innoviva, Inc.’s annual report 10
“The amortization is recorded as a reduction to the royalties from GSK.” SEC filing
“Under our agreements with our collaborative partner GSK, GSK has full responsibility for commercialization of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® .” SEC filing
“We are dependent on GSK for the successful commercialization and development of products under the GSK Agreements.” SEC filing
“Refer to the out-license agreement with Zai Lab and Everest and the Grant Agreement with Gates Foundation in Note 4, "License, Collaboration and Other Arrangements".” SEC filing
“Collaboration Agreement Amendment by and between Theravance, Inc. and Glaxo Group Limited, dated March 3, 2014” SEC filing
“The increase in XACDURO ® ex-U.S. product sales is attributable mainly to product sales under an interim supply agreement with Zai Lab, which is billed at cost.” SEC filing
“We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline.” SEC filing
“For the year ended December 31, 2023, we recognized $ 1.2 million as cost of license revenue under this agreement as a result of the license revenue we earned under the out-licensing agreement with Everest for the same period.” SEC filing
“La Jolla also entered into the Everest commercial supply agreement (the "Everest Supply Agreement") whereby La Jolla will supply Everest a minimum quantity of XERAVA ® and will transfer to Everest certain XERAVA ® -related manufacturing know-how.” SEC filing
“Pursuant to the Paratek Pharmaceuticals, Inc. ("Paratek") License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA ® , including non-exclusive rights to certain issued patents and patent applications covering XERAVA ® .” SEC filing
Companies whose annual reports name Innoviva, Inc. 4
“selective medicines, and Innoviva, Inc., a respiratory-focused healthcare asset management company partnered with Glaxo Group Limited).” SEC filing
“We will purchase the licensed products exclusively from Innoviva.” SEC filing
“License and Collaboration Agreement with Innoviva (SUL-DUR)” SEC filing
“For example, we rely on argenx for VYVGART and VYVGART Hytrulo, NovoCure for OPTUNE, Deciphera for QINLOCK, Innoviva for XACDURO, and BMS for AUGTYRO.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.